Breakthrough Biologic Drug Targets Mutant HER2 Protein for Cancer Treatment

A groundbreaking study from NYU Langone Health has developed a new biologic drug targeting mutant HER2 proteins, promising effective cancer treatments with minimal side effects. This targeted therapy represents a significant advancement in oncology, paving the way for personalized medicine and improved patient outcomes.